Albumin Market to Reach $9.9 billion, Globally, by 2032 at 6.2% CAGR: Allied Market Research

Rise in number of surgical procedures, surge in awareness regarding blood donations, and rise in use of plasma derived albumin in drug development drive the growth of the global albumin market. 

PORTLAND, Ore., Feb. 15, 2024 /PRNewswire/ -- Allied Market Research published a report, titled, "Albumin Market by Type (Human Serum Albumin, Bovine Serum Albumin, and Recombinant Albumin), Application (Therapeutics, Drug Formulation & Vaccines, Component of Media, and Other), and Sales Channel (B2C and B2B): Global Opportunity Analysis and Industry Forecast, 2023-2032". According to the report, the global albumin market was valued at $5.4 billion in 2022, and is projected to reach $9.9 billion by 2032, registering a CAGR of 6.2% from 2023 to 2032. 

Request Sample of the Report on Albumin Market Forecast 2032- https://www.alliedmarketresearch.com/request-sample/2583 

Prime determinants of growth 

Surge in healthcare infrastructure, rise in number of surgical procedures, and increase in awareness regarding the use of albumin are the factors that drive the growth of the global albumin market. However, stringent regulatory requirements hinder market growth. On the contrary, a rise in healthcare expansion is expected to offer remunerative opportunities for the albumin market during the forecast period. 

Report coverage & details: 

What is the Impact of Recession 2023 on Albumin Market? 

• During a recession, the impact on the healthcare industry, including albumin, is moderate. 
• The economic downturns may hinder technology investment. However, the growing number of surgical cases and the rising focus on postoperative care can drive interest in albumin. 

Want to Explore More, Connect to our Analyst- https://www.alliedmarketresearch.com/connect-to-analyst/2583 

The human serum albumin segment to maintain its lead position during the forecast period. 

By type, the human serum albumin segment dominated the market in 2022, accounting for almost two-thirds of the global albumin market and is expected to register highest CAGR of 6.5% during the forecast period owing to the widespread use and diverse applications of human serum albumin in various medical interventions. As a critical component of blood plasma, human serum albumin finds extensive utilization in therapeutic treatments, including fluid resuscitation, wound healing, and the management of hypoalbuminemia. Its compatibility. 

The therapeutics segment to maintain its lead position during the forecast period. 

By application, the therapeutics segment dominated the market in 2022, accounting two-fifths of the global albumin market and is expected to register highest CAGR of 6.7% during the forecast period. This is attributed to the increasing recognition of albumin's therapeutic benefits across diverse medical applications. Its role in addressing critical health challenges such as liver diseases, trauma, and surgical interventions and ability to maintain fluid balance, transport crucial substances, and mitigate protein deficiencies underscores its significance in therapeutic treatments. In addition, ongoing R&D efforts continue to unveil new therapeutic applications for albumin, further propelling its demand. 

The B2B segment to maintain its lead position during the forecast period. 

By sales channel, the B2B segment dominated the market in 2022, accounting almost three-fifths of the global albumin market, owing to increased collaborations and partnerships among pharmaceutical and biotech companies. The B2B model facilitates bulk purchases, ensuring a steady supply of albumin for research, manufacturing, and development activities, thus driving market growth. However, the B2C segment is expected to register highest CAGR of 6.7% during the forecast period owing to direct sale of products from a business (such as pharmaceutical and biotech companies) to individual consumers or end-users. This approach enhances market accessibility, fosters customer engagement, and potentially leads to increased sales and market share, as businesses establish direct connections with end-users in the dynamic albumin market.  

For Purchase Inquiry - https://www.alliedmarketresearch.com/purchase-enquiry/2583 

North America maintains its dominance by 2032 

By region, North America held the highest market share in terms of revenue in 2022, accounting for more than two-fifths of the global albumin market revenue, owing to growing access to advanced technologies and a well-developed network of healthcare & research facilities. In addition, the growing aging population and high incidence of diseased conditions owing to surgical interventions, contribute to the sustained demand for albumin products. However, the Asia-Pacific segment is projected to register highest CAGR of 7.0% during the forecast period owing to increasing healthcare infrastructure development, rising awareness about albumin applications, a surge in surgical procedures, and growing initiatives taken by key players by adopting new strategies. 

Leading Market Players:

• Merck KGaA
• Sartorius AG
• Octapharma AG
• Thermo Fisher Scientific Inc.
• Ventria Bioscience Inc.
• Grifols S.A.
• CSL
• China Biologic Products Holdings Inc.
• Lazuline Bio
• Takeda Pharmaceutical Company Limited

The report provides a detailed analysis of these key players of the global albumin market. These players have adopted different strategy such investment, strategic alliance, product approval, clinical trials, expansion, agreement and acquisition to increase their market share and maintain dominant shares in different regions. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario. 

 About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact

David Correa
1209 Orange Street,
Corporation Trust Center,
Wilmington, New Castle,
Delaware 19801 USA.
Toll Free: +1-800-792-5285
Int'l: +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
[email protected]
Web: https://www.alliedmarketresearch.com  
Follow Us on: LinkedIn Twitter

Logo: https://mma.prnewswire.com/media/636519/Allied_Market_Research_Logo.jpg

SOURCE Allied Market Research